Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...

CSL Ltd (ASX: CSL) shares slumped in 2025, but the outlook may be improving. Here’s why I think CSL could beat the ASX 200 ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track -- Topline phase 3 results for subcutaneous ...

Johnson & Johnson today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...

Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Immune cells are most commonly engineered to kill cancers, but now, scientists have shown the technique makes the gut lining ...